Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT

Recruiting N/A Interventional Study
Moxibustion Hematopoietic Stem Cell Transplantation Hemorrhagic Cystitis Prevention
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
14 – 60
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
266 (estimated)
Sponsor
Yi Zhang · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxib…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Patients are fully aware of the study, participate voluntarily and sign the informed consent form (ICF); 2. Age: 14-60 years; 3. Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or patients with severe aplastic anemia (Severe aplastic anemia…
Contacts

Yi Zhang, Dr

+86 15639790587

zy188603@163.com

CONTACT